Latest news with #QuantraSystem
Yahoo
3 days ago
- Business
- Yahoo
HemoSonics Wins 2025 Supplier Horizon Award from Premier, Inc.
One of 13 companies to receive Premier, Inc.'s Supplier Horizon Award for excellence in improving healthcare performance, HemoSonics' Quantra Hemostasis System provides comprehensive hemostasis analysis in less than 15 minutes DURHAM, N.C., July 17, 2025--(BUSINESS WIRE)--HemoSonics LLC, a medical device company focused on acute bleeding management, today announced it has won the 2025 Supplier Horizon Award from Premier, Inc., a leading technology-driven healthcare performance improvement company. HemoSonics was honored for its Quantra Hemostasis System, an advanced viscoelastic testing device that accelerates decision-making, enhances patient outcomes and reduces healthcare costs by delivering rapid, actionable coagulation assessments in near real-time. One of 13 suppliers to receive the award this year, HemoSonics was recognized for its support of Premier members through exceptional local customer service and engagement, as well as value creation through clinical excellence and a commitment to lower costs. Supplier Horizon Award winners are selected by Premier member committees and have a tenure of less than three years as a Premier contracted supplier. HemoSonics' Quantra Hemostasis System comprises the Quantra Hemostasis Analyzer with QPlus and QStat Cartridges. The Quantra System utilizes innovative SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary ultrasound technology that measures the coagulation properties of a whole blood sample, providing comprehensive coagulation analysis in under 15 minutes. Doctors receive test results quickly during critical and complex surgeries, enabling timely, patient-centered decisions about bleeding management, which improves care and optimizes the use of blood products. "Our mission is to ensure that our clinician partners receive accurate test results quickly during critical, complex surgeries that allow them to make timely patient-centered clinical decisions. By doing so, patients can receive the care that they need at the moment that they need it. We will continue to work tirelessly to ensure that our customers and partners are supported, as we partner with hospitals to deliver better patient outcomes, all while lowering the cost of care," said HemoSonics President and CEO Bob Roda. "We are humbled and proud to receive the Supplier Horizon Award from Premier, Inc." HemoSonics' Quantra System is FDA-cleared for use in cardiovascular and major orthopedic surgery, trauma, and liver transplantation. It requires minimal resources to maintain, is easy to operate and interpret results, and enables hospitals to standardize a clinically and operationally efficient viscoelastic testing program. According to a 2023 Journal of Cardiothoracic Surgery study, Quantra reduced blood component use between 10% and >90%. In addition, the cost of blood products decreased by 41%. "HemoSonics supports Premier members by offering products and services that help improve costs, quality and operations – and deliver overall value," said Bruce Radcliff, Senior Vice President of Supply Chain at Premier. "We're honored to recognize HemoSonics as a Supplier Horizon Award recipient." The Supplier Horizon Award recipients were honored during Premier's annual Breakthroughs Conference & Exhibition, July 15-17, 2025. About HemoSonics HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics' flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. The Quantra System's ease of use and fast interpretation of results enable simple, more efficient point-of-care and laboratory bleeding management. Based in Durham, North Carolina, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to exploring thrombosis and hemostasis. Follow HemoSonics on LinkedIn or visit to learn more. View source version on Contacts Media Contacts: Mindy M. HullMercury Global Partners for HemoSonics+1 415 889 9977 (San Francisco)hemosonics@ Michael Held-HernandezMercury Global Partners for HemoSonics+1 480 306 1154 (Washington D.C.)hemosonics@
Yahoo
27-05-2025
- Business
- Yahoo
HemoSonics Wins Best Medical Device Company in Triangle Business Journal's 2025 Life Sciences Awards
HemoSonics' Quantra Hemostasis System provides comprehensive blood analysis detailing hemostasis in the operating room in less than 15 minutes – a diagnostic breakthrough improving healthcare outcomes DURHAM, N.C., May 27, 2025--(BUSINESS WIRE)--HemoSonics, LLC, a medical device company focused on acute bleeding management, today announced the company has won the Triangle Business Journal 2025 Life Sciences Award in the Best Medical Device Company category for its Quantra Hemostasis System's groundbreaking work in viscoelastic testing. HemoSonics' Quantra Hemostasis System speeds up decision-making in the operating room, improves patient outcomes and reduces healthcare costs by providing optimized coagulation information. According to data from the North Carolina Biotechnology Center, North Carolina is home to 840 life sciences companies, with the lion's share based in the Triangle. The Triangle Business Journal's Life Sciences Awards recognize 12 individuals and research organizations from the Research Triangle, North Carolina (Raleigh, Durham and Chapel Hill region) that are leading and breaking ground in this field. The broad spectrum of the life sciences arena encompasses biotechnology, pharmaceuticals, clinical research, human health, medical devices and diagnostics, and other related fields. The HemoSonics Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer, along with QPlus and QStat Cartridges. The System provides fast, comprehensive whole-blood coagulation analysis at the point of care or in laboratory settings in under 15 minutes, empowering clinicians with information to inform patient-centered decisions that improve care and optimize blood product usage. The Quantra System uses innovative SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary medical-grade ultrasound technology that measures the coagulation properties of a whole blood sample. HemoSonics' Quantra System is FDA-cleared for cardiovascular surgery, trauma, liver transplantation, and major orthopedic surgery. It requires minimal resources to maintain, is easy to operate and interpret, and enables hospitals to standardize a clinically and operationally efficient viscoelastic testing program. "The Research Triangle Park has long been recognized as a catalyst for pioneering technologies in biotechnology, medical devices, and health technology, and this community is one of the key reasons we chose Durham for our headquarters," said Bob Roda, HemoSonics President and CEO. "Innovation is at the heart of what we do at HemoSonics, and we're thrilled to be mentioned alongside companies who are changing the world for the better through medical and scientific advances." HemoSonics' Quantra Hemostasis System technology has received numerous accolades, including the 2024 TIME Best Inventions, 2024 Fast Company Most Innovative Companies (Medtech), 2024 Edison Awards (Point-of-Care and Therapeutic Solutions), and the 2024 Deloitte Fast 500, which recognizes the fastest-growing companies in North America. About HemoSonics: HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics' flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. The Quantra System's easy and fast interpretation enables simple, more efficient point-of-care and laboratory bleeding management. Based in Durham, North Carolina, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to exploring thrombosis and hemostasis. Visit to learn more. View source version on Contacts Media Contacts: Mindy M. HullMercury Global Partners for HemoSonics+1 415 889 9977 (San Francisco)hemosonics@ Michael Held-HernandezMercury Global Partners for HemoSonics+1 480 306 1154 (Washington D.C.)hemosonics@ Sign in to access your portfolio
Business Wire
27-05-2025
- Business
- Business Wire
HemoSonics Wins Best Medical Device Company in Triangle Business Journal's 2025 Life Sciences Awards
DURHAM, N.C.--(BUSINESS WIRE)-- HemoSonics, LLC, a medical device company focused on acute bleeding management, today announced the company has won the Triangle Business Journal 2025 Life Sciences Award in the Best Medical Device Company category for its Quantra Hemostasis System's groundbreaking work in viscoelastic testing. HemoSonics' Quantra Hemostasis System speeds up decision-making in the operating room, improves patient outcomes and reduces healthcare costs by providing optimized coagulation information. "Innovation is at the heart of what we do at HemoSonics, and we're thrilled to be mentioned alongside other Research Triangle Park companies who are changing the world for the better through medical and scientific advances." Share According to data from the North Carolina Biotechnology Center, North Carolina is home to 840 life sciences companies, with the lion's share based in the Triangle. The Triangle Business Journal's Life Sciences Awards recognize 12 individuals and research organizations from the Research Triangle, North Carolina (Raleigh, Durham and Chapel Hill region) that are leading and breaking ground in this field. The broad spectrum of the life sciences arena encompasses biotechnology, pharmaceuticals, clinical research, human health, medical devices and diagnostics, and other related fields. The HemoSonics Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer, along with QPlus and QStat Cartridges. The System provides fast, comprehensive whole-blood coagulation analysis at the point of care or in laboratory settings in under 15 minutes, empowering clinicians with information to inform patient-centered decisions that improve care and optimize blood product usage. The Quantra System uses innovative SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary medical-grade ultrasound technology that measures the coagulation properties of a whole blood sample. HemoSonics' Quantra System is FDA-cleared for cardiovascular surgery, trauma, liver transplantation, and major orthopedic surgery. It requires minimal resources to maintain, is easy to operate and interpret, and enables hospitals to standardize a clinically and operationally efficient viscoelastic testing program. 'The Research Triangle Park has long been recognized as a catalyst for pioneering technologies in biotechnology, medical devices, and health technology, and this community is one of the key reasons we chose Durham for our headquarters,' said Bob Roda, HemoSonics President and CEO. 'Innovation is at the heart of what we do at HemoSonics, and we're thrilled to be mentioned alongside companies who are changing the world for the better through medical and scientific advances.' HemoSonics' Quantra Hemostasis System technology has received numerous accolades, including the 2024 TIME Best Inventions, 2024 Fast Company Most Innovative Companies (Medtech), 2024 Edison Awards (Point-of-Care and Therapeutic Solutions), and the 2024 Deloitte Fast 500, which recognizes the fastest-growing companies in North America. About HemoSonics: HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics' flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. The Quantra System's easy and fast interpretation enables simple, more efficient point-of-care and laboratory bleeding management. Based in Durham, North Carolina, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to exploring thrombosis and hemostasis. Visit to learn more.
Yahoo
29-04-2025
- Business
- Yahoo
HemoSonics Wins 2025 Medical Device Network Excellence Award in the Marketing Category
Award recognizes HemoSonics' impactful marketing and ability to communicate the value of its Quantra Hemostasis System, which provides comprehensive blood analysis detailing hemostasis in the operating room in less than 15 minutes DURHAM, N.C., April 29, 2025--(BUSINESS WIRE)--HemoSonics, LLC, a medical device company focused on acute bleeding management, today announced it has won the 2025 Medical Device Network Excellence Award in the Marketing category for its impactful engagement in promoting its Quantra Hemostasis System. The award recognizes HemoSonics' ability to communicate the value of its Quantra Hemostasis System, engage the healthcare community through educational initiatives, and demonstrate thought leadership in blood management. HemoSonics' Quantra Hemostasis System comprises the Quantra Hemostasis Analyzer with QPlus and QStat Cartridges, providing clinicians with information to inform patient-centered decisions on bleeding management in under 15 minutes, thereby improving care and optimizing blood product usage. The Quantra System uses innovative SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary medical-grade ultrasound technology that measures the coagulation properties of a whole blood sample. HemoSonics' Quantra System is FDA-cleared for cardiovascular surgery, trauma, liver transplantation, and major orthopedic surgery. It requires minimal resources to maintain, is easy to operate and interpret, and enables hospitals to standardize a clinically and operationally efficient viscoelastic testing program. The company has effectively utilized a variety of communication channels, including targeted marketing campaigns, informative webinars, and engaging social media content, to articulate the benefits of its technology. Detailed case studies showcasing successful implementations of the Quantra system have highlighted improvements in patient outcomes and reductions in unnecessary blood transfusions. Additionally, HemoSonics' Quantra Hemostasis System technology has received numerous accolades, including the 2024 TIME Best Inventions, 2024 Fast Company Most Innovative Companies (Medtech), 2024 Edison Awards (Point-of-Care and Therapeutic Solutions), and the 2024 Deloitte Fast 500, which recognizes the fastest-growing companies in North America. HemoSonics has also established itself as a thought leader by addressing critical issues in blood management through various platforms, including earned media coverage, opinion editorial articles, and podcasts. The company's leadership team regularly publishes insightful content discussing emerging trends in coagulation testing and patient blood management. By engaging with key opinion leaders and participating in relevant conferences, HemoSonics shares its expertise while gathering feedback that informs future product development and marketing strategies. "We strive to improve patient outcomes and reduce hospital costs each and every day with the Quantra Hemostasis System. The more hospitals and practitioners who know about and adopt Quantra, the greater our ability to help more people becomes," said Bob Roda, HemoSonics President and CEO. "Marketing, awareness and communications are a key part of our strategy around educating healthcare professionals about how our innovation enables patient-centered decision-making." The Medical Device Network Excellence Awards are an independent recognition program, powered by GlobalData. The awards analyze over one billion datasets to recognize top-tier companies and their achievements across more than 200 countries. This award underscores HemoSonics' position as a leader in innovation and marketing within the medical devices sector. About HemoSonics: HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics' flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. The Quantra System's easy and fast interpretation enables simple, more efficient point-of-care and laboratory bleeding management. Based in Durham, North Carolina, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to exploring thrombosis and hemostasis. Visit to learn more. View source version on Contacts Media Contacts: Mindy M. HullMercury Global Partners for HemoSonics+1 415 889 9977 (San Francisco)hemosonics@ Michael Held-HernandezMercury Global Partners for HemoSonics+1 480 306 1154 (Washington DC)hemosonics@ Sign in to access your portfolio
